US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.12 against a street estimate of 0.16 — a miss of 25.0%.
Analysts rate Dr. Reddy’s Laboratories Ltd ADR a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $14.38.
| Fund | Stake |
|---|---|
| Robeco Institutional Asset Management BV | 2.16% |
| Morgan Stanley - Brokerage Accounts | 1.31% |
| BlackRock Inc | 1.27% |
| Royal Bank of Canada | 1.11% |
| Aikya Investment Management Ltd | 1.02% |
| Renaissance Technologies Corp | 0.88% |
| Dimensional Fund Advisors, Inc. | 0.64% |
| State Street Corp | 0.50% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Brazil’s ANVISA has granted Dr. Reddy’s marketing authorization for generic semaglutide injection. • Brazil has 16.6 million adul | 2026-11-05 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Dr. Reddy’s Laboratories allotted 5,91,270 equity shares on November 4, 2026, after employees exercised stock options under the Dr | 2026-11-04 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • The document is a regulatory filing dated October 29, 2026, covering the earnings-call transcript for the quarter and half year en | 2026-10-29 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • The USFDA has classified its inspection outcome at Dr. Reddy’s FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh, as “Voluntary | 2026-10-29 |
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • Dr. Reddy’s Laboratories disclosed links to the audio and video recordings of its earnings call held on October 23, 2026. • T | 2026-10-26 |
| Current report (6-K) · Q3 FY2027 AUDITOR REVIEW STATUS • Dr. Reddy’s Laboratories filed Deloitte Haskins & Sells LLP’s Limited Review Reports for the unaudited consolidated and stand | 2026-10-26 |
| Quarterly results (6-K) · Q2 FY2027 HEADLINE NUMBERS • Q2FY27 revenue was ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ. • H1FY27 revenue was ₹167,413 Mn, down 3.5% YoY. • Q2FY27 EBITDA w | 2026-10-23 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Dr. Reddy’s Laboratories appointed Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective November 13, | 2026-10-23 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.08 / share ex-date Jul 24, 2026 · pay Aug 5, 2026 | 2026-07-24 |
| Dividend | $0.06 / share ex-date Jul 9, 2026 | 2026-07-09 |
| Split | 5 : 1 effective Nov 5, 2024 | 2024-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Reddy’s Laboratories Ltd ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.